Generic drug

Human medicines European public assessment report (EPAR): Pomalidomide Viatris, pomalidomide, Status: Opinion

Retrieved on: 
Monday, December 18, 2023

Pomalidomide Viatris will be available as 1 mg, 2 mg, 3 mg and 4 mg hard capsules.

Key Points: 
  • Pomalidomide Viatris will be available as 1 mg, 2 mg, 3 mg and 4 mg hard capsules.
  • Pomalidomide Viatris is a generic of Imnovid, which has been authorised in the EU since 05 August 2013.
  • Studies have demonstrated the satisfactory quality of Pomalidomide Viatris and its bioequivalence to the reference product Imnovid.
  • Treatment with Pomalidomide Viatris should be carried out under the supervision of physicians experienced in the treatment of multiple myeloma.

Front End of the Line Semiconductor Equipment Market size to increase by USD 7.56 billion from 2023 to 2028 | Allwin21 Corp., Applied Materials Inc., ASML and more among key companies- Technavio

Retrieved on: 
Thursday, December 14, 2023

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The front end of the line semiconductor equipment market is expected to grow by USD 7.56 billion from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The front end of the line semiconductor equipment market is expected to grow by USD 7.56 billion from 2023 to 2028.
  • The growth of the advanced consumer electronics industry is notably driving the front-end of the line semiconductor equipment market.
  • Front End Of The Line Semiconductor Equipment Market 2024-2028: Company Analysis
    Applied Materials Inc.: The company offers front end of the line semiconductor equipment such as Endura, Alta, Axcela, Aera4, and Aeris-S.
  • View PDF Free Sample Report
    Front End Of The Line Semiconductor Equipment Market 2024-2028: Key Highlights
    The US - semiconductor capital spending market size is estimated to grow at a CAGR of 5.31% between 2023 and 2028.

Global Pharmaceutical Traceability Market Research Report 2023: Blockchain Integration, IoT Sensors, Regulatory Evolution, and Mobile Applications Gaining Momentum - Forecast to 2028

Retrieved on: 
Wednesday, December 13, 2023

The Global Pharmaceutical Traceability Market refers to the industry dedicated to ensuring the transparency, authenticity, and security of pharmaceutical products throughout the supply chain.

Key Points: 
  • The Global Pharmaceutical Traceability Market refers to the industry dedicated to ensuring the transparency, authenticity, and security of pharmaceutical products throughout the supply chain.
  • It's clear that the pharmaceutical industry is undergoing significant changes and challenges, which are driving the adoption of traceability solutions.
  • North America is expected to dominate the pharmaceutical traceability market due to its strong pharmaceutical industry, stringent regulations, technological infrastructure, and focus on patient safety.
  • The pharmaceutical industry faces increasingly stringent regulatory requirements from agencies like the FDA and EMA, particularly related to traceability.

Therapeutic Plasma Exchange Market is Anticipated to Reach USD 2.9 billion, at a CAGR of 7.5% CAGR by 2031 - Report by Transpaency Market Research Inc.

Retrieved on: 
Wednesday, December 13, 2023

WILMINGTON, Del., Dec. 13, 2023 /PRNewswire/ -- The therapeutic plasma exchange market was valued at US$ 1.5 billion in 2022. According to estimates, the market will reach US$ 2.9 billion by the end of 2031, growing at a CAGR of 7.5%.Due to the increasing prevalence of autoimmune diseases worldwide, plasma exchange has become a popular therapeutic intervention. Myasthenia gravis and Guillain-Barré syndrome are two neurological disorders commonly treated with therapeutic plasma exchange. A major driver of the market is the use of therapeutic plasma exchange in treating these conditions.

Key Points: 
  • Therapeutic plasma exchange market growth has been driven by improvements in healthcare infrastructure and the availability of advanced medical treatments in emerging economies.
  • The increasing prevalence of neurological disorders and autoimmune diseases will likely drive the therapeutic plasma exchange market.
  • As the therapeutic plasma exchange market grows, North America is expected to hold the largest market share.
  • Global Therapeutic Plasma Exchange Market: Regional Landscape
    North America is expected to dominate the market for therapeutic plasma exchange market.

Fast Food & Quick Service Restaurants Take Off: Market to Reach US$318 Billion by 2034, Driven by Take-out and Delivery Craze | Future Market Insights, Inc.

Retrieved on: 
Tuesday, December 12, 2023

Request Exclusive Sample Report: Fast Food and Quick Service Restaurant Market Strategic Insights: https://www.futuremarketinsights.com/reports/sample/rep-gb-18651

Key Points: 
  • Request Exclusive Sample Report: Fast Food and Quick Service Restaurant Market Strategic Insights: https://www.futuremarketinsights.com/reports/sample/rep-gb-18651
    Rising consumer spending on fast food, significant R&D activities for producing unique product varieties, and the product's ease of availability are expected to boost the global market.
  • Good flavor, comfort, and affordability in terms of both time and money are some of the key elements driving the quick service restaurant and fast food market.
  • To fulfill the needs of its customers, the fast food and quick service restaurant industry has transformed its business model.
  • •  The global fast food & quick service restaurant market is estimated to register a CAGR of 4.90% with a valuation of US$ 3,18,111.90 million by 2034.

Fast Food & Quick Service Restaurants Take Off: Market to Reach US$318 Billion by 2034, Driven by Take-out and Delivery Craze | Future Market Insights, Inc.

Retrieved on: 
Tuesday, December 12, 2023

Request Exclusive Sample Report: Fast Food and Quick Service Restaurant Market Strategic Insights: https://www.futuremarketinsights.com/reports/sample/rep-gb-18651

Key Points: 
  • Request Exclusive Sample Report: Fast Food and Quick Service Restaurant Market Strategic Insights: https://www.futuremarketinsights.com/reports/sample/rep-gb-18651
    Rising consumer spending on fast food, significant R&D activities for producing unique product varieties, and the product's ease of availability are expected to boost the global market.
  • Good flavor, comfort, and affordability in terms of both time and money are some of the key elements driving the quick service restaurant and fast food market.
  • To fulfill the needs of its customers, the fast food and quick service restaurant industry has transformed its business model.
  • •  The global fast food & quick service restaurant market is estimated to register a CAGR of 4.90% with a valuation of US$ 3,18,111.90 million by 2034.

Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights

Retrieved on: 
Friday, December 8, 2023

Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases.

Key Points: 
  • Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases.
  • This has led to the introduction of innovative products and treatment options in the market, thereby driving the growth of the Red Biotechnology Market .
  • The market for biopharmaceuticals is expected to experience significant growth in the red biotechnology market.
  • The other applications, including animal biotechnology, environmental biotechnology, medical biotechnology, industrial biotechnology, and agricultural biotechnology, also show potential growth.

FDA Approves Bio-Thera Solutions' Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®

Retrieved on: 
Thursday, December 7, 2023

Avzivi® is Bio-Thera's second USFDA approved product and is the second biosimilar researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States.

Key Points: 
  • Avzivi® is Bio-Thera's second USFDA approved product and is the second biosimilar researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States.
  • The FDA approval of Avzivi® was based on a comprehensive analytical, non-clinical and clinical data package submitted by Bio-Thera to the FDA.
  • Extensive analytical characterization between BAT1706 and US and EU Avastin® was conducted on structural, physicochemical, and biological properties to support biosimilarity of BAT1706.
  • The approval of Avzivi® by the FDA will provide lung and colorectal cancer patients a new cost-effective treatment option.

Sun Pharma Canada Launches (PR)ABSORICA LD® (isotretinoin capsules) for Treatment of Severe Acne

Retrieved on: 
Monday, December 4, 2023

BRAMPTON, ON, Dec. 4, 2023 /CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomb: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma") today announces that PRABSORICA LD (isotretinoin capsules) is now available in Canada.

Key Points: 
  • BRAMPTON, ON, Dec. 4, 2023 /CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomb: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma") today announces that PRABSORICA LD (isotretinoin capsules) is now available in Canada.
  • "Knowing the impact that severe acne has on the lives of patients, I look forward to seeing the potential results from this new treatment option."
  • Severe acne causes breakouts that often extend deep into the skin, including cysts and nodules that disfigure the face.
  • Even as severe acne clears, acne scars and pigmentation often appear.5
    "ABSORICA LD brings a novel, micronized formulation of isotretinoin to deal with severe nodular acne to Canadians," said Abhay Gandhi, North America CEO of Sun Pharma.

Levi & Korsinsky, LLP Announces Pendency of Class Action Involving Purchasers of Bloom Energy Corporation Common Shares

Retrieved on: 
Monday, December 4, 2023

SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION, CERTIFICATION OF

Key Points: 
  • SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION, CERTIFICATION OF
    TO: All persons and entities who purchased or otherwise acquired common shares of Bloom Energy Corporation ("Bloom") from July 25, 2018, to March 31, 2020, inclusive:
    PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • YOU ARE ALSO NOTIFIED that Plaintiffs in the Action have reached a proposed settlement of the Action for $3,000,000 in cash (the "Settlement"), that, if approved, will resolve all claims asserted or that could have been asserted in the Action.
  • If you are a member of the Settlement Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund.
  • Inquiries, other than requests for the Notice and Claim Form, should be made to Lead Counsel: